Posted by Michael Wonder on 24 Jan 2018
Lartruvo (olaratumab) approved in Canada for the treatment of advanced soft tissue sarcoma in adults
24 January 2018 - Health Canada has issued a Notice of Compliance with Conditions for Lartruvo (olaratumab).
Olaratumab is a chemotherapy medicine used in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma when treatment with radiation or surgery are not options.
To receive olaratumab, treatment with an anthracycline, such as doxorubicin, must be an appropriate treatment option for the patient. The conditional approval of olaratumab is based on the results of a Phase 2 study that showed a significant improvement in overall survival with a combination of doxorubicin plus olaratumab compared to doxorubicin alone. A confirmatory Phase 3 trial is currently underway to further verify the clinical benefit of olaratumab.
